Anti-CD100 neutralizing antibodies and methods of using the same

Patent metadata

Field	Value
Publication number	US-9676840-B2
Application number	US-201313800713-A
Country	US
Kind code	B2
Filing date	Mar 13, 2013
Priority date	May 8, 2009
Publication date	Jun 13, 2017
Grant date	Jun 13, 2017

Abstract

Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

First claim

What is claimed is:

1. An isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence SEQ ID NO: 9, and wherein the antibody or fragment thereof can specifically bind to CD100.

2. The antibody or fragment thereof of claim 1 , wherein the VL comprises an amino acid sequence identical to SEQ ID NO: 17, except for five or fewer conservative amino acid substitutions.

3. The antibody or fragment thereof of claim 2 , wherein the VL comprises an amino acid sequence identical to SEQ ID NO: 17, except for two or fewer conservative amino acid substitutions.

4. The antibody fragment of claim 1 , which is an Fab fragment, an Fab′ fragment, an F(ab′)2 fragment, an Fd fragment, a single-chain Fv fragment (scFv), or a disulfide-linked Fv fragment (sdFv).

5. The antibody or fragment thereof of claim 1 , which comprises a light chain constant region selected from the group consisting of a human kappa constant region and a human lambda constant region.

6. The antibody or fragment thereof of claim 1 , which comprises a heavy chain constant region or fragment thereof.

7. The antibody or fragment thereof of claim 6 , wherein said heavy chain constant region or fragment thereof is human IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgE or IgD.

8. The antibody or fragment thereof of claim 1 , which binds to human and murine CD100.

9. The antibody or fragment thereof of claim 1 , which inhibits CD100 from binding to a CD100 receptor.

10. The antibody or fragment thereof of claim 9 , wherein said CD100 receptor is Plexin-B1.

11. The antibody or fragment thereof of claim 1 , which is conjugated to a cytotoxic agent, a therapeutic agent, a cytostatic agent, a biological toxin, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, a lymphokine, a heterologous antibody or fragment thereof, a detectable label, polyethylene glycol (PEG), or any combination thereof.

12. The antibody or fragment thereof of claim 11 , wherein the cytotoxic agent is a radionuclide, a biotoxin, an enzymatically active toxin, or any combination thereof.

13. The antibody or fragment thereof of claim 11 , wherein said detectable label is an enzyme, a fluorescent label, a chemiluminescent label, a bioluminescent label, a radioactive label, or a combination thereof.

14. A composition comprising the antibody or fragment thereof of claim 1 , and a carrier.

15. An isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VL comprises the amino acid sequence SEQ ID NO: 17, and wherein the antibody or fragment thereof can specifically bind to CD100.

16. The antibody or fragment thereof of claim 15 , wherein the VH comprises an amino acid sequence identical to SEQ ID NO: 9, except for five or fewer conservative amino acid substitutions.

17. The antibody or fragment thereof of claim 16 , wherein the VH comprises an amino acid sequence identical to SEQ ID NO: 9, except for two or fewer conservative amino acid substitutions.

18. The antibody fragment of claim 15 , which is an Fab fragment, an Fab′ fragment, an F(ab′)2 fragment, an Fd fragment, a single-chain Fv fragment (scFv), or a disulfide-linked Fv fragment (sdFv).

19. The antibody or fragment thereof of claim 15 , which comprises a light chain constant region selected from the group consisting of a human kappa constant region and a human lambda constant region.

20. The antibody or fragment thereof of claim 15 , which comprises a heavy chain constant region or fragment thereof.

21. The antibody or fragment thereof of claim 20 , wherein said heavy chain constant region or fragment thereof is human IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgE or IgD.

22. The antibody or fragment thereof of claim 15 , which binds to human and murine CD100.

23. The antibody or fragment thereof of claim 15 , which inhibits CD100 from binding to a CD100 receptor.

24. The antibody or fragment thereof of claim 23 , wherein said CD100 receptor is Plexin-B1.

25. The antibody or fragment thereof of claim 15 , which is conjugated to a cytotoxic agent, a therapeutic agent, a cytostatic agent, a biological toxin, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, a lymphokine, a heterologous antibody or fragment thereof, a detectable label, polyethylene glycol (PEG), or any combination thereof.

26. The antibody or fragment thereof of claim 25 , wherein the cytotoxic agent is a radionuclide, a biotoxin, an enzymatically active toxin, or any combination thereof.

27. The antibody or fragment thereof of claim 25 , wherein said detectable label is an enzyme, a fluorescent label, a chemiluminescent label, a bioluminescent label, a radioactive label, or a combination thereof.

28. A composition comprising the antibody or fragment thereof of claim 15 , and a carrier.

Assignees

• Vaccinex Inc

Inventors

• Smith Ernest S
• Fisher Terrence Lee

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/02

  Immunomodulators · CPC title